UM  > 健康科學學院
A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy
Shan L.2; Zhuo X.2; Zhang F.1; Dai Y.1; Zhu G.1; Yung B.C.1; Fan W.1; Zhai K.2; Jacobson O.1; Kiesewetter D.O.1; Ma Y.1; Gao G.2; Chen X.1
2018
Source PublicationTheranostics
ISSN18387640
Volume8Issue:7Pages:2018-2030
Abstract

Folate receptor (FR) has proven to be a valuable target for chemotherapy using folic acid (FA) conjugates. However, FA-conjugated chemotherapeutics still have low therapeutic efficacy accompanied with side effects, resulting from complications such as short circulation half-life, limited tumor delivery, as well as high kidney accumulation. Herein, we present a novel FA-conjugated paclitaxel (PTX) prodrug which was additionally conjugated with an Evans blue (EB) derivative for albumin binding. The resulting bifunctional prodrug prolonged blood circulation, enhanced tumor accumulation, and consequently improved tumor therapeutic efficacy. Methods: Fmoc-Cys(Trt)-OH was coupled onto PTX at the 7'-OH position for further synthesis of ester prodrug FA-PTX-EB. The targeting ability was investigated using confocal microscopy and flow cytometry. The pharmacokinetics of this bifunctional compound was also studied. Meanwhile, cell viability was evaluated in normal cells and three cancer cell lines by MTT assay. In vivo therapeutic effect was tested on FR-α overexpressing MDA-MB-231 tumor model. Results: Compared with free PTX, the FA-PTX, PTX-EB and FA-PTX-EB prodrugs increased circulation half-life in mice from 2.19 to 3.82, 4.41, and 7.51 h, respectively. Pharmacokinetics studies showed that the FA-PTX-EB delivered more PTX to tumors than FA-PTX and free PTX. In vitro and in vivo studies demonstrated that FA-EB-conjugated PTX induced potent antitumor activity. Conclusion: FA-PTX-EB showed prolonged blood circulation, enhanced drug accumulation in tumors, higher therapeutic index, and lower side effects than either free PTX or monofunctional FA-PTX and EB-PTX. The results support the potential of using EB for the development of long-acting therapeutics.

KeywordCirculation Half-life Evans Blue Paclitaxel Prodrug Tumor Therapy
DOI10.7150/thno.24382
URLView the original
Indexed BySCI
Language英语
WOS Research AreaResearch & Experimental Medicine
WOS SubjectMedicine, Research & Experimental
WOS IDWOS:000425394000017
Fulltext Access
Citation statistics
Cited Times [WOS]:9   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.National Institute of Biomedical Imaging and Bioengineering
2.Soochow University
Recommended Citation
GB/T 7714
Shan L.,Zhuo X.,Zhang F.,et al. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy[J]. Theranostics,2018,8(7):2018-2030.
APA Shan L..,Zhuo X..,Zhang F..,Dai Y..,Zhu G..,...&Chen X..(2018).A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.Theranostics,8(7),2018-2030.
MLA Shan L.,et al."A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy".Theranostics 8.7(2018):2018-2030.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Shan L.]'s Articles
[Zhuo X.]'s Articles
[Zhang F.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Shan L.]'s Articles
[Zhuo X.]'s Articles
[Zhang F.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Shan L.]'s Articles
[Zhuo X.]'s Articles
[Zhang F.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.